Indian Journal of Critical Care Medicine

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  29 (2025)
Volume  28 (2024)
Volume  27 (2023)
Volume  26 (2022)
Volume  25 (2021)
Volume  24 (2020)
Volume  23 (2019)
Volume  22 (2018)
Volume  21 (2017)
Volume  20 (2016)
Volume  19 (2015)
Volume  18 (2014)
Volume  17 (2013)
Volume  16 (2012)
Volume  15 (2011)
Volume  14 (2010)
Volume  13 (2009)
Volume  12 (2008)
Volume  11 (2007)
Volume  10 (2006)
Volume  9 (2005)
Volume  8 (2004)
Related articles

VOLUME 29 , ISSUE 4 ( April, 2025 ) > List of Articles

Systematic Review/Meta-Analysis

Prevalence, Risk Factors, and Clinical Outcomes of Hypervirulent Klebsiella pneumoniae Strains among Klebsiella pneumoniae Infections: A Systematic Review and Meta-analysis

Danavath Nagendra, Souvik Chaudhuri, Nitin Gupta, Vishal Shanbhag, Vandana K Eshwara, Shwethapriya Rao, Muralidhar Varma, Thejesh Srinivas, Pratibha Todur, PS Priya, Vinutha R Bhat

Keywords : Carbapenem-resistant, Clinical outcomes, Hospital-acquired infections, Hypervirulent Klebsiella pneumoniae, Prevalence, Risk factors

Citation Information : Nagendra D, Chaudhuri S, Gupta N, Shanbhag V, Eshwara VK, Rao S, Varma M, Srinivas T, Todur P, Priya P, Bhat VR. Prevalence, Risk Factors, and Clinical Outcomes of Hypervirulent Klebsiella pneumoniae Strains among Klebsiella pneumoniae Infections: A Systematic Review and Meta-analysis. Indian J Crit Care Med 2025; 29 (4):370-393.

DOI: 10.5005/jp-journals-10071-24957

License: CC BY-NC 4.0

Published Online: 31-03-2025

Copyright Statement:  Copyright © 2025; The Author(s).


Abstract

Aim and background: Hypervirulent Klebsiella pneumoniae (HvKp) is a virulent strain associated with invasive infections. While initially community-acquired, hospital-acquired HvKp (HA-HvKp) and carbapenem-resistant HvKp (CR-HvKp) are increasingly reported. This meta-analysis evaluates the prevalence, risk factors, and clinical outcomes associated with HvKp, including CR-HvKp and HA-HvKp, among Kp infections. Methodology: A systematic search of PubMed, Scopus, Embase, and Cochrane Library was conducted until December 2024. Observational studies comparing HvKp vs classical Kp (cKp), CR-HvKp vs carbapenem-sensitive HvKp (CS-HvKp), and HA-HvKp vs community-acquired HvKp (CA-HvKp) were included. Quality was assessed using the Joanna Briggs Critical Appraisal Tool, and pooled prevalence and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Results: Fifty studies with 6,663 participants were included. The HvKp prevalence was 33.0%, with most studies from Asia, predominantly China. Temporal analysis revealed an increase in HvKp prevalence (27.7% in 2006–2018 to 38.5% in 2019–2024). The CR-HvKp prevalence rose from 9.5% to 16.5% (2016–2024). The HA-HvKp prevalence increased from 25.9 to 47.1%. Key risk factors included diabetes mellitus (OR = 1.56), CA-Kp (OR = 2.59), and hypermucoviscous (HM)-phenotype (OR = 29.79). Complications included liver abscess (OR = 6.35), metastatic spread (OR = 4.74), meningitis (OR = 11.14), and septic shock (OR = 1.30). Mortality was higher in HvKp infections but not statistically significant (p = 0.219). HA-HvKp and immunosuppression were significant CR-HvKp risk factors, with CR-HvKp showing higher mortality. Conclusions: Diabetes mellitus, CA-Kp infections, and HM-phenotype are significant risk factors for HvKp. The rising prevalence of CR-HvKp and HA-HvKp highlights the need for early detection, infection control, and targeted treatment strategies.

PDF Share
  1. Ansari AS. Therapeutic options for the treatment of carbapenem-resistant Enterobacteriaceae infections: Hope in the times of hype and despair. Indian J Crit Care Med 2021;25(7):752–753. DOI: 10.5005/jp-journals-10071-23918.
  2. Bengoechea JA, Sa Pessoa J. Klebsiella pneumoniae infection biology: Living to counteract host defences. FEMS Microbiol Rev 2019;43(2):123–144. DOI: 10.1093/femsre/fuy043.
  3. Pathak A, Tejan N, Dubey A, Chauhan R, Fatima N, Singh SJ, et al. Outbreak of colistin resistant, carbapenemase (blaNDM, blaOXA-232) producing Klebsiella pneumoniae causing bloodstream infection among neonates at a tertiary care hospital in India. Front Cell Infect Microbiol 2023;13:1051020. DOI: 10.3389/fcimb.2023.1051020.
  4. Liu YC, Cheng DL, Lin CL. Klebsiella pneumoniae liver abscess associated with septic endophthalmitis. Arch Intern Med 1986;146(10):1913–1916. PMID: 3532983.
  5. Nayak AR, Ramadoss R, Ramanathan V, Honnarudraiah NK. Emphysematous liver abscess and disseminated hypervirulent Klebsiella pneumoniae infection in a patient from Southern India. Indian J Crit Care Med 2022;26(3):381–383. DOI: 10.5005/jp-journals-10071-24131.
  6. Yu VL, Hansen DS, Ko WC, Sagnimeni A, Klugman KP, von Gottberg A, et al. International Klebsiella Study Group. Virulence characteristics of Klebsiella and clinical manifestations of K. pneumoniae bloodstream infections. Emerg Infect Dis 2007;13(7):986–993. DOI: 10.3201/eid1307.070187.
  7. Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev 2019;32(3):e00001-19. DOI: 10.1128/CMR.00001-19.
  8. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009;48(1):1–12. DOI: 10.1086/595011.
  9. Vandhana V, Saralaya KV, Bhat S, Mulki SS, Bhat AK. Characterization of hypervirulent Klebsiella pneumoniae (Hv-Kp): Correlation of virulence with antimicrobial susceptibility. Int J Microbiol 2022;2022:4532707. DOI: 10.1155/2022/4532707.
  10. Bhardwaj V, Annapandian VM, Sinazer AR, Alva A, Prasad S. Incidence, risk factors and clinical outcomes of patients with hypermucoviscoid Klebsiella in a tertiary intensive care unit. J Glob Infect Dis 2020;12(4):202–207. DOI: 10.4103/jgid.jgid_145_19.
  11. Jung SW, Chae HJ, Park YJ, Yu JK, Kim SY, Lee HK, et al. Microbiological and clinical characteristics of bacteraemia caused by the hypermucoviscosity phenotype of Klebsiella pneumoniae in Korea. Epidemiol Infect 2013;141(2):334–340. DOI: 10.1017/S0950268812000933.
  12. Li W, Sun G, Yu Y, Li N, Chen M, Jin R, et al. Increasing occurrence of antimicrobial-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in China. Clin Infect Dis 2014;58(2):225–232. DOI: 10.1093/cid/cit675.
  13. Catalán-Nájera JC, Garza-Ramos U, Barrios-Camacho H. Hypervirulence and hypermucoviscosity: Two different but complementary Klebsiella spp. phenotypes? Virulence 2017;8(7):1111–1123. DOI: 10.1080/21505594.2017.1317412.
  14. Russo TA, Olson R, Fang CT, Stoesser N, Miller M, MacDonald U, et al. Identification of biomarkers for differentiation of hypervirulent Klebsiella pneumoniae from classical K. pneumoniae. J Clin Microbiol 2018;56(9):e00776-18. DOI: 10.1128/JCM.00776-18.
  15. Liu C, Shi J, Guo J. High prevalence of hypervirulent Klebsiella pneumoniae infection in the genetic background of elderly patients in two teaching hospitals in China. Infect Drug Resist 2018;11:1031–1041. DOI: 10.2147/IDR.S161075.
  16. Xu M, Fu Y, Kong H, Chen X, Chen Y, Li L, et al. Bloodstream infections caused by Klebsiella pneumoniae: Prevalence of blaKPC, virulence factors and their impacts on clinical outcome. BMC Infect Dis 2018;18(1):358. DOI: 10.1186/s12879-018-3263-x.
  17. Kim D, Park BY, Choi MH, Yoon EJ, Lee H, Lee KJ, et al. Antimicrobial resistance and virulence factors of Klebsiella pneumoniae affecting 30-day mortality in patients with bloodstream infection. J Antimicrob Chemother 2019;74(1):190–199. DOI: 10.1093/jac/dky397.
  18. Tang Y, Liu H, Zhao J, Yi M, Yuan Y, Xia Y, et al. Clinical and microbiological prognostic factors of in-hospital mortality caused by hypervirulent Klebsiella pneumoniae infections: A retrospective study in a tertiary hospital in Southwestern China. Infect Drug Resist 2020;13:3739–3749. DOI: 10.2147/IDR.S276642.
  19. Liu C, Guo J. Characteristics of ventilator-associated pneumonia due to hypervirulent Klebsiella pneumoniae genotype in genetic background for the elderly in two tertiary hospitals in China. Antimicrob Resist Infect Control 2018;7:95. DOI: 10.1186/s13756-018-0371-8.
  20. Yang Z, Zhou R, Chen Y, Zhang X, Liu L, Luo M, et al. Clinical and molecular characteristics and antibacterial strategies of Klebsiella pneumoniae in pyogenic infection. Microbiol Spectr 2023;11(4):e0064023. DOI: 10.1128/spectrum.00640-23.
  21. Namikawa H, Yamada K, Sakiyama A, Imoto W, Yamairi K, Shibata W, et al. Clinical characteristics of bacteremia caused by hypermucoviscous Klebsiella pneumoniae at a tertiary hospital. Diagn Microbiol Infect Dis 2019;95(1):84–88. DOI: 10.1016/j.diagmicrobio.2019.04.008.
  22. Qu TT, Zhou JC, Jiang Y, Shi KR, Li B, Shen P, et al. Clinical and microbiological characteristics of Klebsiella pneumoniae liver abscess in East China. BMC Infect Dis 2015;15:161. DOI: 10.1186/s12879-015-0899-7.
  23. Harada S, Aoki K, Yamamoto S, Ishii Y, Sekiya N, Kurai H, et al. Clinical and molecular characteristics of Klebsiella pneumoniae isolates causing bloodstream infections in Japan: Occurrence of hypervirulent infections in health care. J Clin Microbiol 2019;57(11):e01206-19. DOI: 10.1128/JCM.01206-19.
  24. Yao B, Xiao X, Wang F, Zhou L, Zhang X, Zhang J, et al. Clinical and molecular characteristics of multi-clone carbapenem-resistant hypervirulent (hypermucoviscous) Klebsiella pneumoniae isolates in a tertiary hospital in Beijing, China. Int J Infect Dis 2015;37:107–112. DOI: 10.1016/j.ijid.2015.06.023.
  25. Raj S, Sharma T, Pradhan D, Tyagi S, Gautam H, Singh H, et al. Comparative analysis of clinical and genomic characteristics of hypervirulent Klebsiella pneumoniae from hospital and community settings: Experience from a tertiary healthcare center in India. Microbiol Spectr 2022;10(5):e0037622. DOI: 10.1128/spectrum.00376-22.
  26. Liu C, Du P, Xiao N, Ji F, Russo TA, Guo J. Hypervirulent Klebsiella pneumoniae is emerging as an increasingly prevalent K. pneumoniae pathotype responsible for nosocomial and healthcare-associated infections in Beijing, China. Virulence 2020;11(1):1215–1224. DOI: 10.1080/21505594.2020.1809322.
  27. JBI. JBI critical appraisal tools [Internet]. 2024. Available from: https://jbi.global/critical-appraisal-tools.
  28. Comprehensive meta-analysis software full download [Internet]. 2024. Available from: https://meta-analysis.com/pages/full.
  29. Chapter 10: Analysing data and undertaking meta-analyses [Internet]. 2024. Available from: https://training.cochrane.org/handbook/current/chapter-10.
  30. Chapter 7: Considering bias and conflicts of interest among the included studies [Internet]. 2024. Available from: https://training.cochrane.org/handbook/current/chapter-07.
  31. Liu YM, Li BB, Zhang YY, Zhang W, Shen H, Li H, et al. Clinical and molecular characteristics of emerging hypervirulent Klebsiella pneumoniae bloodstream infections in mainland China. Antimicrob Agents Chemother 2014;58(9):5379–5385. DOI: 10.1128/AAC.02523-14.
  32. Yan Q, Zhou M, Zou M, Liu WE. Hypervirulent Klebsiella pneumoniae induced ventilator-associated pneumonia in mechanically ventilated patients in China. Eur J Clin Microbiol Infect Dis 2016;35:387–396. DOI: 10.1007/s10096-015-2551-2.
  33. Yu WL, Lee MF, Chen CC, Tang HJ, Ho CH, Chuang YC, et al. Impacts of hypervirulence determinants on clinical features and outcomes of bacteremia caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Microb Drug Resist 2017;23(3):376–383. DOI: 10.1089/mdr.2016.0018.
  34. Zhang Y, Zhao C, Wang Q, Wang X, Chen H, Li H, et al. High prevalence of hypervirulent Klebsiella pneumoniae infection in China: Geographic distribution, clinical characteristics, and antimicrobial resistance. Antimicrob Agents Chemother 2016;60(10):6115–6120. DOI: 10.1128/AAC.01127-16.
  35. Kim YJ, Kim SI, Kim YR, Wie SH, Lee HK, Kim SY, et al. Virulence factors and clinical patterns of hypermucoviscous Klebsiella pneumoniae isolated from urine. Infect Dis (Lond) 2017;49(3):178–184. DOI: 10.1080/23744235.2016.1244611.
  36. Wu H, Li D, Zhou H, Sun Y, Guo L, Shen D, et al. Bacteremia and other body site infection caused by hypervirulent and classic Klebsiella pneumoniae. Microb Pathog 2017;104:254–262. DOI: 10.1016/j.micpath.2017.01.049.
  37. Guo Y, Wang S, Zhan L, Jin Y, Duan J, Hao Z, et al. Microbiological and clinical characteristics of hypermucoviscous Klebsiella pneumoniae isolates associated with invasive infections in China. Front Cell Infect Microbiol 2017;7:24. DOI: 10.3389/fcimb.2017.00024.
  38. Li J, Ren J, Wang W, Wang G, Gu G, Wu X, et al. Risk factors and clinical outcomes of hypervirulent Klebsiella pneumoniae induced bloodstream infections. Eur J Clin Microbiol Infect Dis 2018;37(4):679–689. DOI: 10.1007/s10096-017-3160-z.
  39. El-Mahdy R, El-Kannishy G, Salama H. Hypervirulent Klebsiella pneumoniae as a hospital-acquired pathogen in the intensive care unit in Mansoura, Egypt. Germs 2018;8(3):140–146. DOI: 10.18683/germs.2018.1141.
  40. Liu C, Guo J. Hypervirulent Klebsiella pneumoniae (hypermucoviscous and aerobactin positive) infection over 6 years in the elderly in China: antimicrobial resistance patterns, molecular epidemiology and risk factors. Ann Clin Microbiol Antimicrob 2019;18(1):4. DOI: 10.1186/s12941-018-0302-9.
  41. Xu M, Fu Y, Fang Y, Xu H, Kong H, Liu Y, et al. High prevalence of KPC-2-producing hypervirulent Klebsiella pneumoniae causing meningitis in Eastern China. Infect Drug Resist 2019;12:641–653. DOI: 10.2147/IDR.S191892.
  42. Zhao Q, Guo L, Wang LF, Zhao Q, Shen DX. Prevalence and characteristics of surgical site hypervirulent Klebsiella pneumoniae isolates. J Clin Lab Anal 2020;34(9):e23364. DOI: 10.1002/jcla.23364.
  43. Hwang JH, Handigund M, Hwang JH, Cho YG, Kim DS, Lee J, et al. Clinical features and risk factors associated with 30-day mortality in patients with pneumonia caused by hypervirulent Klebsiella pneumoniae (hvKP). Ann Lab Med 2020;40(6):481–487. DOI: 10.3343/alm.2020.40.6.481.
  44. Wei DD, Xiong XS, Mei YF, Du FL, Wan LG, Liu Y, et al. Microbiological and clinical characteristics of Klebsiella pneumoniae isolates of K57 capsular serotype in China. Microb Drug Resist 2021;27(3):391–400. DOI: 10.1089/mdr.2018.0456.
  45. Ding Z, Li Z, Tang M, Zeng Z, Song M, Yang K, et al. The molecular characteristics, clinical manifestations, and risk factors of hypervirulent Klebsiella pneumoniae infections in a large teaching hospital in southwest China. Microb Pathog 2022;162:105152. DOI: 10.1016/j.micpath.2021.105152.
  46. Su C, Wu T, Meng B, Yue C, Sun Y, He L, et al. High prevalence of Klebsiella pneumoniae infections in AnHui province: Clinical characteristics and antimicrobial resistance. Infect Drug Resist 2021;14:5069–5078. DOI: 10.2147/IDR.S336451.
  47. Yang F, Wang L, Zhao Q, Wu J, Jiang L, Sheng L, et al. Epidemiological features of Klebsiella pneumoniae infection in the hepatobiliary system of patients in Yantai, China, based on clinical and genetic analyses. Infect Drug Resist 2022;15:3427–3436. DOI: 10.2147/IDR.S369988.
  48. Sheng Z, Li J, Chen T, Zhu Y, Yu X, He X, et al. Clinical and microbiological characteristics of Klebsiella pneumoniae bloodstream infection in a Chinese hospital: Hypervirulent and multiclonal. Infect Drug Resist 2022;15:3981–3990. DOI: 10.2147/IDR.S371477.
  49. Huang Y, Li J, Wang Q, Tang K, Cai X, Li C, et al. Detection of carbapenem-resistant hypervirulent Klebsiella pneumoniae ST11-K64 co-producing NDM-1 and KPC-2 in a tertiary hospital in Wuhan. J Hosp Infect 2023;131:70–80. DOI: 10.1016/j.jhin.2022.09.014.
  50. Kim SH, Jeon CH, Kim HT, Wi YM. Clinical characteristics and manifestations in patients with hypermucoviscous Klebsiella pneumoniae bacteremia from extra-hepatobiliary tract infection. Infection 2023;51(3):689–696. DOI: 10.1007/s15010-022-01940-6.
  51. Rafat C, Messika J, Barnaud G, Dufour N, Magdoud F, Billard-Pomarès T, et al. Hypervirulent Klebsiella pneumoniae, a 5-year study in a French ICU. J Med Microbiol 2018;67:1083–1089. DOI: 10.1099/jmm.0. 000788.
  52. Cubero M, Grau I, Tubau F, Pallarés R, Dominguez MA, Liñares J, et al. Hypervirulent Klebsiella pneumoniae clones causing bacteraemia in adults in a teaching hospital in Barcelona, Spain (2007−2013). Clin Microbiol Infect 2016;22:154–160. DOI: 10.1016/j.cmi.2015. 09.025.
  53. Guo S, Xu J, Wei Y, Xu J, Li Y, Xue R. Clinical and molecular characteristics of Klebsiella pneumoniae ventilator-associated pneumonia in mainland China. BMC Infect Dis 2016;16:608. DOI: 10.1186/s12879-016-1942-z.
  54. Hao Z, Duan J, Liu L, Shen X, Yu J, Guo Y, et al. Prevalence of community-acquired, hypervirulent Klebsiella pneumoniae isolates in Wenzhou, China. Microb Drug Resist 2020;26:21–27. DOI: 10.1089/mdr.2019.0096.
  55. Chen D, Zhang Y, Wu J, Li J, Chen H, Zhang X, et al. Analysis of hypervirulent Klebsiella pneumoniae and classic Klebsiella pneumoniae infections in a Chinese hospital. J Appl Microbiol 2022;132:3883–3890. DOI: 10.1111/jam.15476.
  56. Yang Y, Liu J-H, Hu X-X, Zhang W, Nie T-Y, Yang X-Y, et al. Clinical and microbiological characteristics of hypervirulent Klebsiella pneumoniae (hvKp) in a hospital from North China. J Infect Dev Ctries 2020;14:606–613. DOI: 10.3855/jidc.12288.
  57. Alharbi MT, Almuhayawi MS, Nagshabandi MK, Tarabulsi MK, Alruhaili MH, Gattan HS, et al. Antimicrobial resistance pattern, pathogenicity and molecular properties of hypervirulent Klebsiella pneumonia (hvKp) among hospital-acquired infections in the intensive care unit (ICU). Microorganisms 2023;11:661. DOI: 10.3390/microorganisms11030661.
  58. Li J, Tang M, Liu Z, Xia F, Min C, Hu Y, et al. Molecular and clinical characterization of hypervirulent Klebsiella pneumoniae isolates from individuals with urinary tract infections. Front Cell Infect Microbiol 2022;12:925440. DOI: 10.3389/fcimb.2022.925440.
  59. Fauvet T, Tarantola A, Colot J, Merlet al, Goarant C, Marot B, et al. Mucoviscous characteristics of Klebsiella pneumoniae strains: A factor of clinical severity? Médecine et Maladies Infectieuses 2019;50:500–506. DOI: 10.1016/j.medmal.2019.06.006.
  60. Lee H-C, Chuang Y-C, Yu W-L, Lee N-Y, Chang C-M, Ko N-Y, et al. Clinical implications of hypermucoviscosity phenotype in Klebsiella pneumoniae isolates: Association with invasive syndrome in patients with community-acquired bacteraemia. J Intern Med 2006;259:606–614. DOI: 10.1111/j.1365- 2796.2006.01641.x.
  61. Yu W-L, Ko W-C, Cheng K-C, Lee H-C, Ke D-S, Lee C-C, et al. Association between rmpA and magA genes and clinical syndromes caused by Klebsiella pneumoniae in Taiwan. Clin Infect Dis 2006;42:1351–1358. DOI: 10.1086/503420.
  62. Peirano G, Pitout JD, Laupland KB, Meatherall B, Gregson DB. Population-based surveillance for hypermucoviscosity Klebsiella pneumoniae causing community-acquired bacteremia in Calgary, Alberta. Can J Infect Dis Med Microbiol 2013;24:e61−e64. DOI: 10.1155/2013/828741.
  63. Wei T, Zou C, Qin J, Tao J, Yan L, Wang J, et al. Emergence of hypervirulent ST11-K64 Klebsiella pneumoniae poses a serious clinical threat in older patients. Front Public Health 2022;10:765624. DOI: 10.3389/fpubh.2022.765624.
  64. Hassan NAM, Dawood AHB, Mohamed MF, Sayed SA, Mohamed DH. Distribution, characterization and antibiotic resistance of hypervirulent Klebsiella pneumoniae (hvKp) strains versus classical strains (CKp) causing healthcare associated infections in Sohag University Hospitals. Microbes Infect Dis 2024;5:738–748. DOI: 10.21608/mid.2024.272832.1823.
  65. Moutel M, Peju E, Belan M, Gavaud A, Mira J-P, Charlier C, et al. Hypervirulent Klebsiella pneumoniae-related bacteremia in intensive care unit: A retrospective cohort study. Infect Dis Now 2024;54(5):104892. DOI: 10.1016/j.idnow.2024.104892.
  66. Lederman ER, Crum NF. Pyogenic liver abscess with a focus on Klebsiella pneumoniae as a primary pathogen: An emerging disease with unique clinical characteristics. Am J Gastroenterol 2005;100:322–331. DOI: 10.1111/j.1572-0241.2005.40310.x.
  67. Odouard C, Ong D, Shah PR, Gin T, Allen PJ, Downie J, et al. Rising trends of endogenous Klebsiella pneumoniae endophthalmitis in Australia. Clin Exp Ophthalmol 2017;45:135–142. DOI: 10.1111/ceo.12827.
  68. Monié M, Drieux L, Nzili B, Dicko M, Goursot C, Greffard S, et al. Klebsiella pneumoniae necrotizing fasciitis of the leg in an elderly French woman. Clin Interv Aging 2014;9:1171–1174. DOI: 10.2147/CIA.S60812.
  69. Remya P, Shanthi M, Sekar U. Occurrence and characterization of hyperviscous K1 and K2 serotype in Klebsiella pneumoniae. J Lab Physicians 2018;10:283–288. DOI: 10.4103/JLP.JLP_48_18.
  70. Klebsiella pneumoniae liver abscess: A new invasive syndrome − ScienceDirect [Internet]. 2024. Available from: https://www.sciencedirect.com/science/article/pii/S1473309912702050? via%3Dihub.
  71. Cheng DL, Liu YC, Yen MY, Liu CY, Wang RS. Septic metastatic lesions of pyogenic liver abscess. Their association with Klebsiella pneumoniae bacteremia in diabetic patients. Arch Intern Med 1991;151:1557–1559. PMID: 1872659.
  72. Russo TA, Shon AS, Beanan JM, Olson R, MacDonald U, Pomakov AO, et al. Hypervirulent K. pneumoniae secretes more and more active iron-acquisition molecules than “classical” K. pneumoniae thereby enhancing its virulence. PLoS One 2011;6:e26734. DOI: 10.1371/journal.pone.0026734.
  73. Holden VI, Breen P, Houle S, Dozois CM, Bachman MA. Klebsiella pneumoniae siderophores induce inflammation, bacterial dissemination, and HIF-1α stabilization during pneumonia. mBio 2016;7:e01397–16. DOI: 10.1128/mBio.01397-16.
  74. Predictors of hypervirulent Klebsiella pneumoniae infections: A systematic review and meta-analysis − ScienceDirect [Internet]. 2024. Available from: https://www.sciencedirect.com/science/article/pii/S0195670123000580?via%3Dihub.
  75. Namikawa H, Oinuma K-I, Yamada K, Kaneko Y, Kakeya H, Shuto T. Differences in severity of bacteraemia caused by hypermucoviscous and non-hypermucoviscous Klebsiella pneumoniae. Int J Antimicrobial Agents 2023;61(5):106767. DOI: 10.1016/j.ijantimicag.2023.106767.
  76. Shankar C, Veeraraghavan B, Nabarro LEB, Ravi R, Ragupathi NKD, Rupali P. Whole genome analysis of hypervirulent Klebsiella pneumoniae isolates from community and hospital acquired bloodstream infection. BMC Microbiol 2018;18(1):6. DOI: 10.1186/s12866-017-1148-6.
  77. Feng Y, Lu Y, Yao Z, Zong Z. Carbapenem-resistant hypervirulent Klebsiella pneumoniae of sequence type 36. Antimicrob Agents Chemother 2018;62:e02644-17. DOI: 10.1128/AAC.026 44-17.
  78. Ouyang P, Jiang B, Peng N, Wang J, Cai L, Wu Y, et al. Characteristics of ST11 KPC-2-producing carbapenem-resistant hypervirulent Klebsiella pneumoniae causing nosocomial infection in a Chinese hospital. J Clin Lab Anal 2022;36:e24476. DOI: 10.1002/jcla.24476.
  79. Wang Q, Chen M, Ou Q, Zheng L, Chen X, Mao G, et al. Carbapenem-resistant hypermucoviscous Klebsiella pneumoniae clinical isolates from a tertiary hospital in China: Antimicrobial susceptibility, resistance phenotype, epidemiological characteristics, microbial virulence, and risk factors. Front Cell Infect Microbiol 2022;12:1083009. DOI: 10.3389/fcimb.2022.1083009.
  80. Lin JC, Siu LK, Fung CP, Tsou HH, Wang JJ, Chen CT, et al. Impaired phagocytosis of capsular serotypes K1 or K2 Klebsiella pneumoniae in type 2 diabetes mellitus patients with poor glycemic control. J Clin Endocrinol Metab 2006;91(8):3084–3087. DOI: 10.1210/jc.2005- 2749.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.